Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons

Journal of Receptors and Signal Transduction

Volumn 32, Issue 3, 2012, Pages 156-162

  Ozcan, Mete ^a   Ayar, Ahmet ^b  

^a FIRAT UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Action potential; Antiepileptic drug; Calcium imaging; Dorsal root ganglion; Levetiracetam; Pain

Indexed keywords

CALCIUM ION; ETIRACETAM; FURA 2;

ACTION POTENTIAL; AFTERHYPERPOLARIZATION; ANIMAL CELL; ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; DOSE RESPONSE; ELECTRIC RESISTANCE; EXCITABILITY; FLUORESCENCE IMAGING; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROMODULATION; NONHUMAN; PATCH CLAMP; RAT; SENSORY NERVE CELL; SPINAL GANGLION; WHOLE CELL;

ACTION POTENTIALS; ANALGESICS; ANIMALS; ANTICONVULSANTS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; EPILEPSY; FLUORESCENT DYES; FURA-2; GANGLIA, SPINAL; NEURONS; PAIN; PATCH-CLAMP TECHNIQUES; PIRACETAM; RATS; SENSORY RECEPTOR CELLS;

RATTUS;

EID: 84860529299     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2012.672993     Document Type: Article

References (36)

1. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010, 11, 1230-1239.
2. rd. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med 2009, 10, 586-593.
3. Bennett GJ. Neuropathic pain: new insights, new interventions. Hosp Pract (Minneap) 1998, 33, 95-8, 101.
4. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009, 122, S22-S32.
5. Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009, 9, 71-78.
6. Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001, 21, 1375-1388.
7. Nash EM, Sangha KS. Levetiracetam. Am J Health Syst Pharm 2001, 58, 1195-1199. (Pubitemid 32622545)
8. Ardid D, Lamberty Y, Alloui A, Coudore-Civiale MA, Klitgaard H, Eschalier A. Antihyperalgesic efect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol 2003, 473, 27-33. (Pubitemid 36851625)
9. Enggaard TP, Klitgaard NA, Sindrup SH. Specifc efect of levetiracetam in experimental human pain models. Eur J Pain 2006, 10, 193-198. (Pubitemid 43255205)
10. Ozcan M, Ayar A, Canpolat S, Kutlu S. Antinociceptive efcacy of levetiracetam in a mice model for painful diabetic neuropathy. Acta Anaesthesiol Scand 2008, 52, 926-930. (Pubitemid 351951754)
11. Klitgaard H. Levetiracetam: the preclinical profle of a new class of antiepileptic drugs? Epilepsia 2001, 42 Suppl 4, 13-18. (Pubitemid 32802081)
12. McCarter GC, Reichling DB, Levine JD. Mechanical transduction by rat dorsal root ganglion neurons in vitro. Neurosci Lett 1999, 273, 179-182. (Pubitemid 29430179)
13. Klusáková I, Dubový P. Experimental models of peripheral neuropathic pain based on traumatic nerve injuries-an anatomical perspective. Ann Anat 2009, 191, 248-259.
14. Vyklický L, Knotková-Urbancovä H. Can sensory neurones in culture serve as a model of nociception? Physiol Res 1996, 45, 1-9. (Pubitemid 26091963)
15. Vanegas H, Schaible H. Efects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 2000, 85, 9-18. (Pubitemid 30110739)
16. Ozcan M, Ayar A, Alcin E, Ozcan S, Kutlu S. Efects of levobupivacaine and bupivacaine on intracellular calcium signaling in cultured rat dorsal root ganglion neurons. J Recept Signal Transduct Res 2010, 30, 115-120.
17. Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother 2005, 19, 35-43. (Pubitemid 40594048)
18. Klitgaard H, Pitkänen A. Antiepileptogenesis, neuroprotection, and disease modifcation in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003, 5 Suppl 1, S9-16.
19. Archer DP, Lamberty Y, Wang B, Davis MJ, Samanani N, Roth SH. Levetiracetam reduces anesthetic-induced hyperalgesia in rats. Anesth Analg 2007, 104, 180-185. (Pubitemid 46360444)
20. Sliva J, Dolezal T, Prochazkova M, Votava M, Krsiak M. Preemptive levetiracetam decreases postoperative pain in rats. Neuro Endocrinol Lett 2008, 29, 953-957.
21. Rossi S, Mataluni G, Codecà C, Fiore S, Buttari F, Musella A, Castelli M, Bernardi G, Centonze D. Efects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 2009, 16, 360-366.
22. Jorns TP, Johnston A, Zakrzewska JM. Pilot study to evaluate the efcacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. Eur J Neurol 2009, 16, 740-744.
23. Holbech JV, Otto M, Bach FW, Jensen TS, Sindrup SH. The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. Eur J Pain 2011, 15, 608-614.
24. Del Pozo E, Pereira-Pérez E, González-Contreras LG. [Te efectiveness of levetiracetam in the treatment of neuropathic pain]. Rev Neurol 2011, 53, 65-72.
25. Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001, 10, 279-286. (Pubitemid 32705452)
26. Pisani A, Bonsi P, Martella G, De Persis C, Costa C, Pisani F, Bernardi G, Calabresi P. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004, 45, 719-728. (Pubitemid 38890968)
27. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007, 4, 18-61. (Pubitemid 46107329)
28. Palma E, Ragozzino D, Di Angelantonio S, Mascia A, Maiolino F, Manfredi M, Cantore G, Esposito V, Di Gennaro G, Quarato P, Miledi R, Eusebi F. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 2007, 48, 1842-1849. (Pubitemid 47537430)
29. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001, 306, 5-8. (Pubitemid 32524284)
30. Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann EJ. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003, 45, 661-671. (Pubitemid 36980822)
31. Lee CH, Lee CY, Tsai TS, Liou HH. PKA-mediated phosphorylation is a novel mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 channels. Biochem Pharmacol 2008, 76, 225-235.
32. Nadeau H, McKinney S, Anderson DJ, Lester HA. ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons. J Neurophysiol 2000, 84, 1062-1075. (Pubitemid 30657493)
33. Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett 2008, 436, 289-293.
34. Cataldi M, Lariccia V, Secondo A, di Renzo G, Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1, 4, 5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ter 2005, 313, 720-730. (Pubitemid 40604173)
35. Costa C, Martella G, Picconi B, Prosperetti C, Pisani A, Di Filippo M, Pisani F, Bernardi G, Calabresi P. Multiple mechanisms underlying the neuroprotective efects of antiepileptic drugs against in vitro ischemia. Stroke 2006, 37, 1319-1326. (Pubitemid 43731883)
36. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43, 9-18. (Pubitemid 34215447)